BeiGene scrambles to find new Abraxane supplier as Chinese inspectors order halt on imports, citing Bristol Myers failure
In a slap in the face aimed right at one of the world’s largest drugmakers, BeiGene $BGNE said today that it is being forced by Chinese officials to halt imports of the cancer drug Abraxane.
According to the China-based BeiGene, the China National Medical Products Administration — or NMPA — ordered the halt following an inspection of one of Bristol Myers’ US facilities used to make the drug. That’s a rare event in the global drug making world, where the FDA is known for its regular citations for overseas drug manufacturers.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.